A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.
about
Differentially expressed genes in adult familial myelodysplastic syndromes.Myelodysplastic syndrome with erythroid aplasia following pure red cell aplasia.Is myelodysplastic related acute myelogenous leukemia a distinct entity from de novo acute myelogenous leukemia? Potential for targeted therapies.Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation.Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.The role of rHuEpo in low-risk myelodysplastic syndrome patients.Enhanced growth of myelodysplastic colonies in hypoxic conditionsMyelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications.Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155.Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies.Inflammatory reactive oxygen species-mediated hemopoietic suppression in Fancc-deficient miceEctopic expression of C/EBPalpha and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasiaMyelodysplastic features in visceral leishmaniasis.On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.Molecular cloning of t(2;7)(p24.3;p14.2), a novel chromosomal translocation in myelodysplastic syndrome-derived acute myeloid leukemia.Matrix metalloproteinase inhibitor reduces apoptosis induction of bone marrow cells in MDS-RA.Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications.Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes.Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes.A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes.Clinical importance of transforming growth factor-beta but not of tumor necrosis factor-alpha gene polymorphisms in patients with the myelodysplastic syndrome belonging to the refractory anemia subtype.Survivin Expression in Acute Leukemias and Myelodysplastic Syndromes
P2860
Q33197003-8D561688-1D45-4D01-888A-84F2D84746D1Q33363214-57BF19FD-6C55-4DB3-8DCF-D842033E5F36Q34265233-5D99B6F3-DBB1-4ED6-8C09-26208CDC3033Q34435506-42AFC372-1974-467D-834A-D51CAB98164EQ35001132-DC03F192-D2BB-4E31-95A1-8508A148A9E5Q35034815-4DE77232-8A0D-4DE1-B18E-D5504E0869B9Q35186892-3E028947-629A-484B-A82C-0D949738F4A6Q36194667-745C4AD1-46F0-471F-9F2B-EB9F2BE80068Q36916269-BE3A8247-CC6B-49D5-9982-1CDA155B4B74Q36961721-8C15931F-2690-41F2-93FA-EA53AD8B4964Q36988558-BEC4C28B-99EF-4648-B370-A6DADEC655F2Q39411436-0D49C9B4-1682-4907-9EB4-BEC66062B171Q40318729-74EE8335-E19B-41DB-A47B-F163BFAD2D71Q42527369-0DD66C1D-C2BB-4ED5-B6E2-A1595B83492BQ42548780-DA087744-273E-4CFB-9A1A-AE6F58C840A3Q42662362-F99DC5F5-17AB-46C5-B4E8-E5E93DD03F2FQ44201023-56E0D0CF-FC4C-4B29-A5E8-05DBBB4ED8A3Q46544698-D228C79B-8647-43B7-BCA2-DECB7643A18CQ46849239-3EB77315-6776-4CFE-BBC0-B9CFD4A32206Q46901611-113E1913-A701-4213-9FF1-E1BB616686F1Q47383738-C107AF82-E395-4FC5-90A1-AF0754970CD2Q52952665-F64705BA-A8BE-4EBE-A608-72042AF47E00Q53272408-78FD8D5B-C86C-4FD0-B983-FCDADDDE7D9FQ53394494-2A72D836-1F86-4794-9BD9-FF8559992D70Q53509755-E3FCB011-CDE4-44A5-AC41-74F03070A170Q54530259-0710C634-B7EC-4F44-8D1E-320AD907DA10Q54667319-91C68832-8E0A-4C12-BAFF-57BC753EBFBEQ57786461-55F6D495-3E28-46CA-8496-5F45D1AF653F
P2860
A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
A hypothesis for the pathogene ...... mplications for new therapies.
@ast
A hypothesis for the pathogene ...... mplications for new therapies.
@en
type
label
A hypothesis for the pathogene ...... mplications for new therapies.
@ast
A hypothesis for the pathogene ...... mplications for new therapies.
@en
prefLabel
A hypothesis for the pathogene ...... mplications for new therapies.
@ast
A hypothesis for the pathogene ...... mplications for new therapies.
@en
P356
P1433
P1476
A hypothesis for the pathogene ...... implications for new therapies
@en
P2093
C Rosenfeld
P2888
P356
10.1038/SJ.LEU.2401618
P50
P577
2000-01-01T00:00:00Z
P5875
P6179
1043125068